MouseandHamsterModelsdevelopfattyliverdiseaseandNASHin2-3months
2-3个月即可通过饮食诱导成功的小鼠和仓鼠非酒精脂肪肝和非酒精脂肪性肝炎模型
SANDIEGO,May25,--BioDuro,LLC,aleadingdrugdiscoveryanddevelopmentservicesorganization,announcedtodaytheavailabilityoftwonewpreclinicalmodelsforNon-alcoholicsteatohepatitis(NASH)thathighlyresembleclinicalprogressionofthediseaseanddosoinamatterof2-3months.Themodelsincludemouseandhamsterspecies,andmanifestallthehallmarksofNASHdisease,enablingdrugdeveloperstoevaluatebroadclassesofdrugtargets,includingmetabolicinflammationandfibrogenicpathwaysalike.
圣地亚哥，年5月25日-保诺科技有限公司作为一家引领新药研发服务的科技公司今天宣布了两个新的非酒精脂肪性肝炎临床前疾病模型推向市场，这两个非酒精脂肪性肝炎疾病模型包括小鼠和仓鼠两个种属，诱导时间为2到3个月，与疾病的临床进展高度吻合，表现出非酒精脂肪性肝炎的所有疾病特征，使得新药研发人员可以评价广泛的药物靶点，包括代谢，炎症和纤维化相关的信号通路。
NASHisasevereformofnon-alcoholicfattyliverdisease(NAFLD),andisexpectedtobetheleadingcauseofliverfailureandtransplantinthenextfiveyears.Despitethehighprevalence,thereisnoFDAapprovedtherapy.Accordingly,biopharma
